Pharmacyclics announces clinical abstracts on ibrutinib to be presented at ASCO annual meeting

Pharmacyclics, Inc. (NASDAQ: PCYC) today announced that clinical abstracts on Bruton's Tyrosine Kinase inhibitor, ibrutinib (formerly, PCI-32765) have been selected for oral presentations at the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO), June 1-5, 2012 in Chicago, IL.

The update on data presented for the first time will specifically include: 1) safety and efficacy data from the phase II CLL single agent trial in treatment-naive patients; 2) safety and efficacy data from the phase Ib/II CLL combination trial with ofatumumab in relapsed or refractory patients and 3) safety and efficacy data from the phase Ib CLL combination trial with bendamustine and rituximab in relapsed or refractory patients. Pharmacyclics plans to present a material update on the ibrutinib clinical development program in a press release after the ASCO oral presentations on Monday, June 4, 2012 and expects to hold a conference call as well on Wednesday, June 6, 2012 at 1:30 PM PT/4:30 PM ET.

Oral Presentation at ASCO, Chicago, IL (June 1-5, 2012)Date/Time: Monday, June 4, 2012; 10:15 AM — 10:30 AM (CT)
Location: E354a
Abstract # 6507: The Bruton's tyrosine kinase inhibitor PCI-32765 in treatment-naive chronic lymphocytic leukemia patients: Interim results of a phase Ib/II study. Dr. John C. Byrd et al., The Ohio State University, Columbus, Ohio.
This Abstract was selected to be presented at the "Best of ASCO Meetings."

Oral Presentation at ASCO, Chicago, IL (June 1-5, 2012)Date/Time: Monday, June 4, 2012; 10:30 AM — 10:45 AM (CT)
Location: E354a
Abstract # 6508: A phase Ib/II study evaluating activity and tolerability of BTK inhibitor PCI-32765 and ofatumumab in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and related diseases. Dr. Samantha Mary Jaglowski et al. The Ohio State University, Columbus, Ohio. 

Poster Discussion Session at ASCO, Chicago, IL (June 1-5, 2012)Date/Time: Friday, June 1, 2012; 4:30 PM — 5:30 PM (CT)
Location: S405
Abstract # 6515: Combination of the Bruton's tyrosine kinase inhibitor PCI-32765 with bendamustine/rituximab in patients with relapsed/refractory chronic lymphocytic leukemia: Interim results of a phase Ib/II study.  Dr. Susan M. O'Brien et al. MD Anderson Cancer Center, Houston, Texas.